Peptide record

TPDB92841

Sema-OH Cell-penetrating Peptides standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92841
Sema-OH
Cell-penetrating Peptides
Delivery and barrier-penetrating peptides
CPPsite3.0
standard
No
A 9-aa standard natural cell-penetrating peptides peptide sequence curated from CPPsite3.0, with an available 3D structural model.
N-terminal: Biotinylation
Sequence
GNKKGRNRR
Physicochemical Analysis
C42H80N22O12
ADCEQHILMFPSTWYV
R
1085.24
12.71
5
0
0
+5
5.27
-3.233
0.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
0
A
3
R
2
N
0
D
0
C
0
E
0
Q
2
G
0
H
0
I
0
L
2
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 3 N: 2 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 0 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C42H80N22O12
1085.24
12.71
+5
5.27
-3.233
Free
L
Linear
Biotinylation
NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)O
Evidence Records 1 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

CHO pgs745

Assay & Model

Athymic nu/nu female mice
Athymic nu/nu female mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
silver-based nanoparticles (AgNPs) labelled with CF555 fluorescent dye
Endosomal compartments
AgNP-Sema-OH and, to a lesser extent, AgNP-AA-Sema-OH entered the NRP1-transfected CHO pgs745 cells
HS-dependent pathway with the C-end rule (CendR) mechanism
In vitro and in vivo
CTHHHHHHHHTTTHHHHCC
Additional Detail Fields 1 fields
CTHHHHHHHHTTTHHHHCC